Across TCGA pan-cancer cohorts, SIGLEC15 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SIGLEC15 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SIGLEC15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SIGLEC15 expression acts as an unfavorable survival marker.

LIHC are the cancer types where SIGLEC15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.164	0.704	.025	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: SIGLEC15 tumor-vs-normal RNA expression · all SIGLEC15 data types